Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (1879)	5/14/1999 10:50:00 AM
From: Jeff Chan	Read Replies (1) \| Respond to of 14101

FYI... I just spoke to one of our Pfizer reps (they're co-marketing Celebrix with Searle). He indicated that the price for Celebrix is $37.00/month in Canada as opposed to $85.00/month in the US. Also, the autopsy reports indicated that the 10 deaths originally reported by Celebrix users were, apparently, not as a result of the drug. Jeff C

To: Mark Bartlett who wrote (1879)	5/16/1999 8:55:00 AM
From: Tom Drolet	Respond to of 14101

Mark: This is a web page reference that I tripped across. It is a US Venture Capital Co.-- H.L. Montgomery-- that is funding work on Cancer Immunoligy response mechanisms. I put it here with DMX-- not to push the MGM Group-- but because of the (sorry)- very lengthy discussion on Cancer treatment and Immune response stuff that WF 10 may be able to help. Just background. hlmontgomery.com